Kenvue Inc Dossier
Qualitative Analysis
Business overview
Kenvue Inc. (NYSE: KVUE) is the world's largest pure-play consumer health company by revenue. Spun off from Johnson & Johnson in 2023, Kenvue operates through three primary business segments: Self Care, Skin Health and Beauty, and Essential Health. The company's portfolio features globally recognized, science-backed household brands including Tylenol, Neutrogena, Aveeno, Listerine, Band-Aid, and Zyrtec. Kenvue serves approximately 1.2 billion people across more than 165 countries, leveraging an extensive global scale and a robust healthcare professional network. The company's legal entity identifier (LEI) is 5493008HSF8L4M2LIJ82.
Research as of 29 Jul 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A comprehensive initiative designed to enhance organizational efficiencies, optimize cost structures, and rebalance resources to improve information technology infrastructure and overall operational agility.
Expected impact: Aims to optimize the cost structure, rebalance resources, and generate significant cost savings to expand operating margins.
An initiative approved by the Board of Directors on February 17, 2026, to optimize Kenvue's operating model, transform its supply chain, reduce complexity, and drive operational efficiencies while strengthening core capabilities.
Expected impact: Expected to cut the global workforce by about 3.5% and drive long-term operational efficiencies and cost savings.
Kenvue's climate transition plan focused on reducing Scope 1 and Scope 2 greenhouse gas emissions by 42% by 2030, using 100% renewable electricity across operations by 2030, and having 75% of key suppliers set science-based climate targets by 2028.
Expected impact: Decarbonization of operations and value chain. As of the end of 2025, Kenvue achieved a 41% absolute emissions reduction in direct operations and sourced 76.2% of global electricity from renewables.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To combine Kimberly-Clark's dominance in personal care with Kenvue's powerhouse portfolio of science-based health brands, creating a global health and wellness leader with approximately $32 billion in annual net revenues and unlocking $2.1 billion in anticipated run-rate synergies.
Financial impact: Expected to be accretive to Kimberly-Clark's adjusted EPS by Year 2, with total anticipated run-rate synergies of $2.1 billion.